Shalov Stone Bonner & Rocco LLP Announces Class Action Against Immucor, Inc.
* Reuters is not responsible for the content in this press release.
NEW YORK, NY, Aug 27 (MARKET WIRE) --
Shalov Stone Bonner & Rocco LLP announces that a class action lawsuit has
been filed on behalf of all purchasers of the publicly traded securities
of Immucor, Inc. ("Immucor" or the "Company") (NASDAQ: BLUD) between
October 19, 2005 and April 23, 2009 (the "Class Period"), who were
damaged thereby. The lawsuit is pending in the United States District
Court for the Northern District of Georgia against Immucor and certain of
its officers and directors.
The complaint alleges that, throughout the Class Period, defendants
materially misrepresented Immucor's business operations by failing to
disclose that Immucor was operating in violation of the U.S. antitrust
laws. On April 24, 2009, Immucor issued a press release announcing, in
part, that it had "received a subpoena from the United States Department
of Justice, Antitrust Division, pertaining to an investigation of possible
violations of the federal criminal antitrust laws in the blood reagents
industry. On this news, Immucor's closing stock price fell from $20.98 on
April 23, 2009 to $15.35 on the next trading day.
Shalov Stone Bonner & Rocco LLP has extensive experience in the
prosecution of lawsuits on behalf of investors. For more information
about the firm, please visit its website at: www.lawssb.com
If you purchased Immucor stock and would like additional information about
your rights, please contact investor rights attorney Amanda C. Scuder, at
Shalov Stone Bonner & Rocco LLP, 485 Seventh Avenue, Suite 1000, New York,
New York 10018 (telephone: (212) 239-4340; email: ascuder@lawssb.com).
Attorney advertising. Prior results do not guarantee a similar outcome.
CONTACT:
Amanda C. Scuder - Attorney
SHALOV STONE BONNER & ROCCO LLP
Telephone: (212) 239-4340
Facsimile: (212) 239-4310
Email: Email Contact
http://www.lawssb.com
Copyright 2009, Market Wire, All rights reserved.
-0-
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.



Follow Reuters